STRIBILD
Peakelvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
NDAORALTABLET
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
6/8 — Strong
STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) by Gilead Sciences is cytochrome p450 3a inhibitors [moa]. Approved for cytochrome p450 3a inhibitor [epc]. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STRIBILD is a fixed-dose combination tablet containing elvitegravir (integrase inhibitor), cobicistat (CYP3A inhibitor), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor). It is indicated for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults. The product works through multiple mechanisms: elvitegravir inhibits HIV integrase, while cobicistat enhances the bioavailability of elvitegravir and other protease inhibitors through CYP3A inhibition, and the two nucleoside/nucleotide analogs inhibit reverse transcriptase. STRIBILD represents a complete single-tablet regimen that simplifies HIV treatment but has been partially displaced in the market by newer formulations with improved renal tolerability profiles.
$0.0BPart D
6.9 years to LOEMechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
Started Feb 2015
21 enrolled
HIVAIDSSleep Disorders
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
Started Dec 2014
72 enrolled
HIV-1 Infection
STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)
Started Nov 2014
30 enrolled
HIVIllicit Drug User
Sleep and Cognition After Atripla to Stribild Switch
Started Sep 2014
30 enrolled
HIV
An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
Started Sep 2014
30 enrolled
HIV-2 Infection
Worked on STRIBILD at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.